Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics

References

• Balant L. Les sulfonylurées hypoglycémiantes: un problème de génération? Considérations pharmacocinétiques et pharmacodynamiques. Diabète Metab. 1978; 4: 135–1431. Balant L. Les sulfonylurées hypoglycémiantes: un problème de génération? Considérations pharmacocinétiques et pharmacodynamiques. Diabète Metab. 1978; 4: 135–143
   PubMedGoogle Scholar
• Campbell D. B., Adriaenssens P., Hopkins Y. W., Gordon B. Pharmacokinetics and metabolism of gliclazide: a review. “Gliclazide in the Treatment of Diabetes”, H. Keen, A. D. S. Caldwell, M. Murphy, C. Bowker. Academic Press, London 1980; 71–822. Campbell D. B., Adriaenssens P., Hopkins Y. W., Gordon B. Pharmacokinetics and metabolism of gliclazide: a review. “Gliclazide in the Treatment of Diabetes”, H. Keen, A. D. S. Caldwell, M. Murphy, C. Bowker. Academic Press, London 1980; 71–82
   Google Scholar
• Dorner M., Brogard J. M., Pinget M., Sapin R., Demangeat C., Comte F. Le peptide C et son intért en diabétologie. J. Annu. Diabetol. Hotel Dieu. 1979; 75–913. Dorner M., Brogard J. M., Pinget M., Sapin R., Demangeat C., Comte F. Le peptide C et son intért en diabétologie. J. Annu. Diabetol. Hotel Dieu. 1979; 75–91
   PubMedGoogle Scholar
• Fussgaenger R. D., Goberna R., Hinz M., Jaros P., Karsten C., Pfeiffer E. F., Raptis S. Comparative studies on the dynamics of insulin secretion following HB 419 and tolbutamide of the perfused isolated rat pancreas and the perifused isolated pieces and islets of rat pancreas. Horm. Metab. Res. 1969, Suppl. 1: 34–404. Fussgaenger R. D., Goberna R., Hinz M., Jaros P., Karsten C., Pfeiffer E. F., Raptis S. Comparative studies on the dynamics of insulin secretion following HB 419 and tolbutamide of the perfused isolated rat pancreas and the perifused isolated pieces and islets of rat pancreas. Horm. Metab. Res. 1969, Suppl. 1: 34–40
   Google Scholar
• Haupt E., Koeberich W., Beyer J., Schoeffling K. Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. 1. Dose response relations and repeated administration in diabetic subjects. Diabetologia. 1971; 7: 449–4545. Haupt E., Koeberich W., Beyer J., Schoeffling K. Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. 1. Dose response relations and repeated administration in diabetic subjects. Diabetologia. 1971; 7: 449–454
   PubMed Web of Science ®Google Scholar
• Loubatieres A., Mariani M. M., Ribes G., Alric R. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide). Acta Diabet. Lat. 1973; 10: 261–2826. Loubatieres A., Mariani M. M., Ribes G., Alric R. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide). Acta Diabet. Lat. 1973; 10: 261–282
   Google Scholar
• Luft R., Wajngot A., Efendic S. On the pathogenesis of maturity-onset diabetes. Diabetes Care 1981; 4: 58–637. Luft R., Wajngot A., Efendic S. On the pathogenesis of maturity-onset diabetes. Diabetes Care 1981; 4: 58–63
   PubMed Web of Science ®Google Scholar
• Raptis S., Rau R. M., Schroeder K. E., Faulhaber J. D., Pfeiffer E. F. Comparative study of insulin secretion following repeated administration of glucose, tolbutamide and glibenclamide (HB 419) in diabetic and non-diabetic human subjects. Horm. Metab. Res. 1969, Suppl. 1: 65–728. Raptis S., Rau R. M., Schroeder K. E., Faulhaber J. D., Pfeiffer E. F. Comparative study of insulin secretion following repeated administration of glucose, tolbutamide and glibenclamide (HB 419) in diabetic and non-diabetic human subjects. Horm. Metab. Res. 1969, Suppl. 1: 65–72
   PubMedGoogle Scholar
• Ratzmann K. P., Schulz B., Heinke P., Michaelis D. Quantitative and qualitative changes in the early insulin responses to glucose in subjects with impaired carbohydrate tolerance. Diabetes Care 1981; 4: 85–919. Ratzmann K. P., Schulz B., Heinke P., Michaelis D. Quantitative and qualitative changes in the early insulin responses to glucose in subjects with impaired carbohydrate tolerance. Diabetes Care 1981; 4: 85–91
   PubMed Web of Science ®Google Scholar
• Reville P., Thierry R., De La Harpe E, Doerflinger M. A., Stephan F. Le traitement du diabète de la maturité par le gliclazide. L'insulinosécrétion apres hyperglycémie provoquée I.V. Diabète. 1973; 21: 264–26810. Reville P., Thierry R., De La Harpe E, Doerflinger M. A., Stephan F. Le traitement du diabète de la maturité par le gliclazide. L'insulinosécrétion apres hyperglycémie provoquée I.V. Diabète. 1973; 21: 264–268
   Google Scholar